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Polyinosinic:polycytidylic acid (Poly(I:C))Increasing epidemiological and experimental evidence implicates gestational infections as one important factor
involved in the pathogenesis of several neuropsychiatric disorders. Corresponding preclinical model systems
based upon maternal immune activation (MIA) by treatment of the pregnant female have been developed.
These MIA animal model systems have been successfully used in basic and translational research approaches,
contributing to the investigation of the underlying pathophysiological mechanisms at the molecular, cellular
and behavioral levels. The present article focuses on the application of a speciﬁc MIA rodent paradigm, based
upon treatment of the gestating damwith the viral mimic polyinosinic–polycytidilic acid (Poly(I:C)), a synthetic
analog of double-stranded RNA (dsRNA) which activates the Toll-like receptor 3 (TLR3) pathway. Important ad-
vantages and constraints of this animalmodelwill be discussed, speciﬁcally in light of gestational infection as one
vulnerability factor contributing to the complex etiology of mood and psychotic disorders, which are likely the
result of intricate multi-level gene × environment interactions. Improving our currently incomplete understand-
ing of the molecular pathomechanistic principles underlying these disorders is a prerequisite for the develop-
ment of alternative therapeutic approaches which are critically needed in light of the important drawbacks
and limitations of currently available pharmacological treatment options regarding efﬁcacy and side effects.
The particular relevance of the Poly(I:C) MIA model for the discovery of novel drug targets for symptomatic
and preventive therapeutic strategies in mood and psychotic disorders is highlighted in this review article.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Fig. 1. The rodent maternal immune activation model. Gestational infection is mimicked
by immunological stimulation of the gestating dam with immune-stimulating agents
such as Poly(I:C). Responses in thematernal compartment include systemic immune acti-
vation characterized by increased levels of proinﬂammatory cytokines. Consequently, the
integrity of the placental barrier becomes compromised, allowing entrance ofmaternally-
derived cytokines into the fetal circulation and inducing inﬂammatory responses in the
developing fetus, including the brain. This leads to structural and developmental distur-
bances associated with various neuropsychiatric diseases such as schizophrenia and
depression.
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Strong epidemiological and experimental evidence suggests early
life adversity, including the pre-, peri- and early postnatal period, as a
common factor involved in the pathogenesis of some of themost debil-
itating mental illnesses, including mood and psychotic disorders
(Brown & SES, 2002; Fortier et al., 2007; Meyer et al., 2007; Meyer
et al., 2009b; Atladottir et al., 2010; Bitanihirwe et al., 2010; Boksa,
2010; Brown & DEJ, 2010; Piontkewitz et al., 2012; Vuillermot et al.,
2012; Zhang et al., 2012; Burt et al., 2013; Khan et al., 2014; Meyer,
2014b). These two complex neuropsychiatric disorders are linked at
several levels, including the parallel presentation of psychotic and de-
pressive symptoms frequently observed in patients and emerging evi-
dence for overlapping etiological and pathophysiological features (see
for review Buckley et al., 2009). Speciﬁcally, stressful events during em-
bryogenesis are hypothesized to have deleterious consequences on fetal
brain development (Meyer et al., 2009b; Piontkewitz et al., 2012),
which may contribute to the manifestation of mental illness later in
life (Koenig et al., 2002; Winter et al., 2009; Boksa, 2010; Lin et al.,
2012; Khan et al., 2014). Recently, growing support for gestational in-
fection stress as one particular condition impinging on the developing
brain and associated with neurobehavioral alterations in adulthood,
has been obtained fromepidemiological studies aswell as fromanalyses
in experimental animalmodels (see for review:Meyer et al., 2007#539;
Rapoport et al., 2005; Meyer et al., 2009b; Boksa, 2010; Markham & KJI,
2011; Khandaker et al., 2013).
The normal course of fetal development requires a speciﬁc balance
between the maternal and fetal environments of constitutively
expressed cytokines – small pleiotropic signaling molecules released
as part of the innate immune response –with the placenta constituting
the structural interface for maternal–fetal–immune interaction (Mehler
& Kessler, 1998; Cannon et al., 2002; Deverman & Patterson, 2009;
Dickerson & Bilkey, 2013; Garay et al., 2013). In the case of hemochorial
placentation, the type of placentation occurring in mammals including
humans and rodents, the placenta allows for direct contact between
the maternal and fetal compartments (Colucci et al., 2011), and fetal
syntiotrophoblast cells are exposed to mediators of the maternal im-
mune response (Moffett & Loke, 2006). While under physiological con-
ditions, this process is tightly controlled (Munn et al., 1998), maternally
derived cytokines and chemokines may excessively permeate the fetal
compartment in cases of severe maternal immune challenge (Fig. 1).
As a consequence of the fetal immune system not being prepared to ad-
equately respond to severe proinﬂammatory inﬂuences, the cytokine
equilibrium in the developing brain is thrown off-balance (Welberg
et al., 2000; Seckl, 2004;Mueller & Bale, 2008). This cytokine imbalance
can compromise themolecular, structural and functional integrity of the
developing brain with long-lasting consequences contributing to the
development of neuropsychiatric disturbances later in life (Zhao & JPS,
1998; Patterson, 2007; Meyer et al., 2009b; Burd et al., 2012).
Epidemiological studies have repeatedly conﬁrmed a relationship
between maternal immune activation (MIA) and psychiatric disorders
such as schizophrenia (Brown & SES, 2002; Buka et al., 2008; Brown &
DEJ, 2010) (Table 1), autism-spectrum disorder (ASD) (Martin et al.,
2008; Fox et al., 2012), as well as neurological impairments including
cerebral palsy (Rasiah Vigneswaran et al., 2003; Folkerth, 2005) in
adult offspring. The long-lasting impact of gestational infection on off-
spring brain structure and function is further evidenced by analyses of
post-mortem tissue samples of exposed individuals diagnosed with
psychiatric disorders schizophrenia, ASD, bipolar disorder and depres-
sion (Lewis & Levitt, 2002; Patterson, 2007; Jaaro-Peled et al., 2009;
Brown & DEJ, 2010). Epidemiological examinations of large population
samples are a potent tool for the investigation of associative relation-
ships between certain environmental conditions, prenatal infections,
and disease risk, the development of neuropsychiatric disorders. How-
ever, testing causal associations and elucidating the underlying cellular
and molecular pathophysiological mechanisms – a prerequisite for thedevelopment of novel treatment options – are dependent on the estab-
lishment and use of animal models.
With regard to the effects of gestational infection on adult
offspring brain function and behavioral phenotypes, speciﬁc animal
models of MIA based upon administration of immunogenic substances
to the pregnant female have been developed. The most commonly
used approaches rely on mimicking maternal infection by treat-
ment with the bacterial endotoxin lipopolysaccharide (LPS) and the
double-stranded RNA (dsRNA) analog polyinosinic:polycytidylic acid
(Poly(I:C)) (Fig. 1). While LPS and Poly(I:C) elicit distinct molecular
proﬁles – targeting the toll-like receptor (TLR) 4 and TLR3 pathways re-
spectively – both MIA paradigms have been successfully used to estab-
lish animal models for some of the most common and debilitating
neuropsychiatric disorders, including schizophrenia, autism and de-
pression (Fatemi et al., 1999; Fatemi et al., 2002a, 2002b; Fatemi et al.,
2002b; Smith et al., 2007; Garbett et al., 2012; Dickerson & Bilkey,
2013; Bauman et al., 2014; Khan et al., 2014). Despite continuous
efforts, the neurobiological basis of these severe mental illnesses,
which compromise the quality of life of patients and their families as
well as posing signiﬁcant socioeconomic burden on society (Kessler
et al., 2003), remain incompletely understood currently available
pharmacotherapeutic options present withmajor limitations: they pro-
vide relief from only some of the symptoms and fail to cure the respec-
tive disorders, are effective only in a limited number of affected patients,
Table 1
Human studies describing the role of maternal immune activation in neuropsychiatric diseases.
Neuropsychiatric
disorder(s)
Reference Study design Pathogen(s)/Pathogenic
mechanism(s)
Results Effect of infection on
risk for relevant
neuropsychiatric
disorder(s)
Affective disorders Brown et al., 1995 Ecological study Inﬂuenza virus Reduced risk of developing affective disorders
after putative exposure to inﬂuenza epidemic
⇓
Major depression Machon et al., 1997 Ecological study Inﬂuenza virus Increase in major depression diagnoses after
putative exposure to inﬂuenza epidemic
⇑
Major depression Mino et al., 2000 Ecological study Inﬂuenza virus No effect found ⇔
Major depression Pang et al., 2009 Nested case–control
study
Various viral agents
(total effect analyzed)
No effect found ⇔
Schizophrenia/affective
psychotic disorders
Takei et al., 1993 Ecological study Inﬂuenza virus Increased schizophrenia diagnoses after
putative exposure to inﬂuenza epidemic;
decrease in affective psychotic disorder
diagnoses
⇑ (SCZ)
⇓ (affective psychotic
disorder)
Schizophrenia and
depressive illness
Cannon et al., 1996 Follow-up on cohort
study
Inﬂuenza virus Increased risk for depressive illness among
exposed individuals; no signiﬁcant effect on
schizophrenia diagnoses found
⇑ (MDD)⇔ (SCZ)
Schizophrenia and
affective psychosis
Cahill et al., 2002 Ecological study Poliovirus No effect found ⇔
Schizophrenia Watson et al., 1984 Ecological study Various infectious
diseases
Increased risk for schizophrenia in individuals
with birth years directly following time periods
of high prevalence of infectious diseases
⇑
Schizophrenia Mednick et al., 1988 Ecological study Inﬂuenza virus Increased risk for schizophrenia in individuals
exposed to inﬂuenza during gestation
⇑
Schizophrenia Torrey et al., 1988 Ecological study Various viral agents
(total effect analyzed)
Increased risk for schizophrenia after putative
exposure to measles, varicella zoster, polio;
inﬂuenza showed effect just below signiﬁcance
level; no effect of rubella or mumps found
⇑ (measles, varicella
zoster, polio)
⇔ (rubella, mumps)
Schizophrenia Barr et al., 1990 Ecological study Inﬂuenza virus Increased schizophrenia diagnoses in
individuals exposed to periods of high incidence
of inﬂuenza during gestation
⇑
Schizophrenia O'callaghan et al., 1991 Ecological study Inﬂuenza Increase in births of schizophrenic individuals 5
months after peak infection prevalence
⇑
Schizophrenia Crow & done, 1992 Cohort study Inﬂuenza virus No effect found ⇔
Schizophrenia Adams et al., 1993 Ecological study Inﬂuenza virus Increased schizophrenia diagnoses after
inﬂuenza epidemics in three cohorts of patients
⇑
Schizophrenia Susser et al., 1994 Ecological study Inﬂuenza virus No effect found ⇔
Schizophrenia Suvisaari et al., 1999 Ecological study Poliovirus Increased schizophrenia diagnoses in
individuals exposed to periods of high incidence
of poliomyelitis during gestation
⇑
Psychotic disorders Brown et al., 2000 Follow-up on cohort
study
Rubella virus Increased risk for nonaffective psychosis among
individuals exposed to rubella during gestation
⇑
Psychotic disorders Buka et al., 2001 Nested case–control
study
Analysis of antibodies
in maternal serum at birth
Association between elevated maternal levels of
IgG, IgM and antibodies against HSV-2 (but not
against several other pathogens) and
schizophrenia diagnoses in offspring
⇑ (HSV-2)
Schizophrenia Limosin et al., 2003 Case–control study Inﬂuenza virus Increased risk for schizophrenia in individuals
exposed to inﬂuenza during gestation
⇑
Schizophrenia Brown et al., 2004 Nested case–control
study
Inﬂuenza virus Increased risk for schizophrenia in individuals
exposed to inﬂuenza during gestation
⇑
Schizophrenia Brown et al., 2005 Nested case–control
study
Toxoplasma gondii Increased risk for schizophrenia spectrum
disorders in subjects with high maternal levels
of T. gondii antibody
⇑
Schizophrenia Babulas et al., 2006 Cohort study Maternal genital/
reproductive infections
Increased risk for schizophrenia and
schizophrenia spectrum disorders in individuals
exposed during the periconceptional period
⇑
Schizophrenia Mortensen et al., 2007 Case–control study Toxoplasma gondii Increased risk for schizophrenia in subjects with
high maternal levels of T. gondii IgG antibody
⇑
Psychotic disorders Buka et al., 2008 Nested case–control
study
Herpes simplex virus Increased risk of developing psychoses in
Offspring of mothers seropositive for herpes
simplex
⇑
Schizophrenia Sorensen et al., 2009 Cohort study Various bacterial agents
(individual/grouped
effects analyzed)
Increased risk for schizophrenia in individuals
exposed to various bacterial pathogens during
gestation
⇑
Schizophrenia Ellman et al., 2010 Case–control study IL-8 Increased risk for presenting neuroanatomical
changes that have been previously linked to
schizophrenia among cases exposed to IL-8 in
utero
⇑
215S. Reisinger et al. / Pharmacology & Therapeutics 149 (2015) 213–226and treatment is frequently associated with a range of unpleasant side
effects, severely compromising patient compliance rates (Rush et al.,
2006; Warden et al., 2007; Gaynes, 2009).In the case of major depressive disorder (MDD), the dominant phar-
macological treatment approach involves the use of selective serotonin
or norepinephrine reuptake inhibitors (SSRIs/SNRIs) as well as tricyclic
216 S. Reisinger et al. / Pharmacology & Therapeutics 149 (2015) 213–226antidepressants (Davidson, 2010). In more resistant cases, monoamine
oxidase inhibitors (MAOIs) are also prescribed, though some argue
these continue to be underused (Shulman et al., 2013). Besides drug
therapy, non-pharmacological approaches including various forms of
psychological interventions such as cognitive behavioral therapy or in-
terpersonal psychotherapy, are known to show considerable efﬁcacy
(see for review: Cuijpers et al., 2008; Gloaguen et al., 1998; van Hees
et al., 2013). For medium and severe chronic depression, the most suc-
cessful treatment is thought to involve a combination ofmedication and
psychotherapy (Pampallona et al., 2004; de Maat et al., 2007; Cuijpers
et al., 2009). In response to the urgent need for the development of
rapidly acting antidepressants, novel treatment alternatives including
the use of deep transcranial magnetic stimulation (TMS) of the anterior
cingulate cortex and the application of the N-methyl-D-aspartate
(NMDA) antagonist ketamine are emerging (Mayberg et al., 2005;
Machado-Vieira et al., 2009). Currently, due to its relatively modest
side effects and high therapeutic potential, TMS is proposed to replace
electroconvulsive therapy, the most ancient psychiatric intervention in
MDD (Micallef-Trigona, 2014).
In schizophrenia, on the other hand, available treatments are mainly
effective in alleviating the positive symptoms, including delusions and
hallucinations, with a major lack of treatment options available to ad-
dress the negative (mainly avolition, anhedonia and reduced affect)
and cognitive symptoms of the disease (Pratt et al., 2012). Commonly
applied therapeutic strategies rely on the use of ﬁrst-generation or
second-generation antipsychotics (FGA/SGAs), all of which directly
and/or indirectly target the dopamine receptor type 2 (D2) (Pratt
et al., 2012). Routine clinical approaches are either based upon mono-
therapy with antipsychotics or a combination treatment with other
pharmacological (often antidepressant) or non-pharmacological (main-
ly psychotherapy) treatments (Kane et al., 2003). While the possibility
to medically reduce the burdensome positive symptoms of schizophre-
nia is immensely beneﬁcial for the afﬂicted patients, the alleviation of
negative and cognitive symptoms still represents unmet important
therapeutic needs. However, the discovery of novel therapeutic avenues
is largely dependent on improving our understanding of the intricate
neurobiological processes underlying the symptoms experienced by af-
fected patients which, importantly, builds upon the availability of useful
and trustworthy animalmodels. Considering the constraints in the ther-
apeutic potential of most commonly used drug treatments and the lim-
ited progress in the discovery and implementation of alternative
approaches, the development of entirely new preclinical model systems
emerges as an important prerequisite for future developments. These
models should have a high degree of construct validity, reﬂecting
identiﬁed genetic and/or environmental factors contributing to the
pathophysiology of the disease, rather than predicting the efﬁcacy of
currently available drugs which do not address a considerable part of
the symptomatic spectrum of the disease.
Here, animal models of gestational infection constitute an exciting
advance, since they reproduce in an experimentally amenable setting
the contribution of particular aspects of adverse early life events,
based upon infectious stress, a known risk factor for the development
of mood and psychotic disorders (Table 1). The present review strives
to provide an overview of the use of animalmodels for the experimental
assessment of the role of MIA in the pathophysiology of these disorders,
focusing on the Poly(I:C) paradigm and its utility for drug discovery.
2. Animal models of maternal
immune activation in neuropsychiatric research
Animal models of complex diseases of the human mind are always
subject to particular scrutiny, within the scientiﬁc community as well
as the general public. Attempting to recapitulate in laboratory animals,
mainly rodents, behavioral features which in part (such as hallucina-
tions, delusions, suicidal thoughts or feelings of worthlessness) are con-
sidered inherent to thehuman species and are not ascertainable in otheranimals, represents amajor challenge. However, the pathophysiological
complexity of most psychiatric disorders, involving a plethora of gene ×
environment interactions, further underscores the important role of rel-
evant and reliable animal models. These models serve as experimental
tools for the investigation of the pathophysiological mechanisms in-
volved, a prerequisite for the identiﬁcation of novel therapeutic strate-
gies. Making no pretense to reproduce in its entirety the spectrum of
neuropathological features giving rise to the multitude of symptoms
presented in the patient population, a single animal model can have
its usefulness—when properly validated according to established qual-
ity criteria.
The classic framework for the assessment of validity of animal
models is built upon the three major pillars of construct, face and pre-
dictive validity (Willner, 1997; Pollak et al., 2010; Belzung & Lemoine,
2011). In neuropsychiatric research amajor focus is placed on construct
validity as a key determinant for successful drug discovery, mandating
the diseasemodel to be based upon known genetic and/or environmen-
tal risk factors — which allows for a recapitulation of the etiological
principles involved (Nestler & Hyman, 2010; Fernando & Robbins,
2011; Pratt et al., 2012). Face validity, referring to the analogy between
symptoms/features presented in patients and experimental animals can
be achieved to varying degrees for animal models of neuropsychiatric
disorders, depending on the possibility to reproduce human behavioral
features in laboratory animals, as outlined above. Predictive validity –
comparable response to treatment of the observed animal phenotype
and the human symptomatology – may be considered as less in-
formative in some instances, given the known therapeutic limitations
of currently available drug treatments for major psychiatric conditions,
including schizophrenia and depression. With this background,
neurodevelopmental models are gaining major attention as the knowl-
edge about the relevance of pre- and perinatal environmental insults as
major risk factors for the mood and psychotic disorders is increasing
(Ansorge et al., 2007; Brown, 2011). Stress-based models, including
early maternal separation (Vetulani, 2013), social isolation (Fone &
Porkess, 2008) and toxicological approaches such as gestational expo-
sure to methyl-azoxymethanol (Lodge & Grace, 2009), have been
most useful in depression and schizophrenia research (Maniam &
Morris, 2010; Baek et al., 2011;Marsden et al., 2011;Moller et al., 2013).
Given the relevance of gestational infections as a risk factor for the
development of severe neuropsychiatric illnesses (Table 1), several dif-
ferent approaches for the modeling of MIA in laboratory animals have
been developed. The currently mostly employed experimental strate-
gies are either based upon i) the use of live viruses, or ii) the administra-
tion of immunogenic substances mimicking bacterial or viral infections
in the host organism.
The direct application of live viruses constituted the ﬁrst animal
models of gestational infection. Here, the aim was to most closely
mimic the epidemiological observations after the inﬂuenza epidemic
of 1957 (Mednick et al., 1988; Mednick et al., 1994), by the use of live
inﬂuenza virus (H1N1) (Fatemi et al., 1999; Fatemi et al., 2002a,
2002b). Subsequently, several seminal ﬁndings consolidating the link
between prenatal infection and brain and behavioral derangements
later in life, have been obtained using this approach (see for review:
Meyer & Feldon, 2010; Meyer et al., 2009a). While the inﬂuenza
model of MIA is unarguably closest to the human situation, it also en-
compasses certain limitations inherent to the use of live pathogens in
experimental animals. Importantly, laboratory manipulations involving
the handling of infectious agents require the establishment and execu-
tion of preventive safety measures in order to minimize personal risks
for the experimenters involved. These considerations are unnecessary
in the models of viral and bacterial infection relying on the administra-
tion of immunogenic substances to the pregnant female, which induce
the activation of infection-associated intracellular pathways through
binding to TLRs. The two most commonly used approaches are based
upon the application of LPS and Poly(I:C):LPS, a gram-negative bacterial
cell wall component which mimics bacterial infections binding to TLR4
Fig. 2. Involvement of the TLR3 and TLR4 signaling pathways in neuropsychiatric disorders. Several components and processes of the Toll-like receptor (TLR) 3 and TLR4 pathways have
been implicated in the etiology of neuropsychiatric diseases as illustrated by selected reports from literature: 1,2 — TLR (Muller et al., 2012; Hoyo-Becerra et al., 2013; Keri et al., 2014;
Lin et al., 2014; Pandey et al., 2014); 3 — SARM1 (Lin & Hsueh, 2014; Lin et al., 2014); 4 — NF-kB (Koo et al., 2010; Keri et al., 2014); 5 — proinﬂammatory cytokines (Dunn et al.,
2005; Dowlati et al., 2010; Hannestad et al., 2011; Hiles et al., 2012a, 2012b; Valkanova et al., 2013); 6 — DRIIs (Schlaak et al., 2012; Hoyo-Becerra et al., 2013); 7 — MAPK (Wefers
et al., 2012; Mitic et al., 2014; Reus et al., 2014). Abbreviations: AP-1 (=activator protein 1), DRIIs (=depression-related interferon-induced genes), FADD (=Fas-associated protein
with death domain), IKKs (=inhibitors of NF-kB kinase), IRAKs (=interleukin-1 receptor-associated kinase) 1 and 4, IRF3 (=interferon regulatory factor 3), MAL (=MyD88 adaptor-
like), MAPK (=mitogen-activated protein kinase), MyD88 (=myeloid differentiation primary response gene 88), NF-kB (=nuclear factor kappa-light-chain-enhancer of activated B
cells), PKCε (=protein kinase C epsilon), SARM1 (=sterile alpha and TIRmotif containing 1), TAK1 (=transforming growth factor beta activated kinase-1), TAB (=TAK binding protein)
1 and 3, TLR (Toll-like receptor) 3 and 4; TRAF3 (=TNF receptor-associated factor 3), TRAF6/RIP1 (=TNF receptor-associated factor 6/receptor interacting protein 1), TRAM (=TRIF-re-
lated adaptor molecule), TRIF (=TIR-domain-containing adapter-inducing interferon-β).
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produced dsRNA analog binding to TLR3. DsRNAs are exclusively pro-
duced in the context of viral infection and constitute potent activators
of themammalian immune system (Matsumoto & Seya, 2008), eliciting
a plethora of intracellular signaling pathways including activation of
the IkappaB kinase, extracellular signal-regulated kinase, and c-Jun
N-terminal kinase, among others (Park et al., 2006). Additional rele-
vance for both approaches (TLR3- and TLR4-dependent) MIA animal
models is conferred by independent observations linking individual
molecular elements of the signaling cascades elicited by TLR3 and
TLR4 activation to the pathophysiology of neuropsychiatric disorders
(Fig. 2). The focus of the present review is speciﬁcally on the signiﬁ-
cance of the Poly(I:C) MIA model in preclinical research on mood and
psychotic disorders and its applicability for psychiatric drug validation
and discovery.
In light of the epidemiological evidence (Table 1), the Poly(I:C) MIA
model presentswith a high degree of construct validity and has been re-
peatedly demonstrated to induce behavioral features related to schizo-
phrenia, autism and depression in adult offspring (face validity).
Moreover, structural and functional aberrations in particular brain re-
gions in adult offspring after Poly(I:C)-assisted MIA overlap with
known pathophysiological features of mood and psychotic disorders
(Fig. 3). To date, phenotypes related to schizophrenia have been most
intensively investigated in mice and rats. Speciﬁcally, deﬁcits in
prepulse inhibition, modulated sensorimotor gating, and decreased la-
tent inhibition – related to the attentional control of selective associa-
tive learning and working memory – have been repeatedly conﬁrmed
in different laboratories as extensively reviewed elsewhere (Meyer
et al., 2009a; Meyer & Feldon, 2010, 2012) (Meyer, 2014b). Lately, evi-
dence for anhedonic deﬁcits – a central manifestation in depressive dis-
orders and a prominent negative symptom of schizophrenia – after
prenatal immune challenge by Poly(I:C) is emerging in rats and mice
(Khan et al., 2014; Missault et al., 2014). Interestingly, enhanced behav-
ioral despair, as assessed by tests related to depression-like phenotypes
in rodents, has been so far only documented in mouse Poly(I:C) off-
spring (Chen et al., 2011; Khan et al., 2014). Several of these behavioral
deﬁcits, together with related deﬁciencies in brain structure and func-
tion, have been found to be reversible by schizophrenia-speciﬁc phar-
macotherapy (Table 2), suggesting a good predictive validity of theFig. 3. Structure and function of brain regions impacted by Poly(I:C)-assisted MIA. Abnormalit
Poly(I:C) MIA have been documented (Babri et al., 2013). Alterations in the mesolimbic path
been identiﬁed in Poly(I:C)MIA offspring (Zuckermanet al., 2003). Prenatal Poly(I:C) is reported
level reductions reported in Poly(I:C)MIA offspring (Ozawaet al., 2006) are sensitive to antipsyc
offspring from Poly(I:C)MIA and neural synchrony disturbances between the Hipp and PFC, asso
et al., 2012; Dickerson & Bilkey, 2013). Compromised levels of dopamine (Bitanihirwe et al., 201
in levels of GABA are reported in the Hipp and Amyg (Nyffeler et al., 2006b) in offspring of Poly
ventricles (Piontkewitz et al., 2012). Abbreviations: HPA: hypothalamic pituitary adrenal, VTA:
Hipp: hippocampus, PFC: prefrontal cortex, GABA: γ-aminobutyric acid, Poly(I:C): polyinosinicPoly(I:C) MIA model. However, the relevance of the concept of predic-
tive validity for the development of novel experimental animal models
and for drug discovery for mood and psychotic disorders has been chal-
lenged (Nestler & Hyman, 2010; Fernando & Robbins, 2011; Pratt et al.,
2012) based on the fact that “traditional” screensmay preferentially de-
tect compounds with “traditional”modes of action.
Together with the epidemiological evidence, results obtained in an-
imal models indicate an involvement of gestational infection in the de-
velopment of several neuropsychiatric disorders, the underlying
molecular pathophysiological principles of which remain to be fully elu-
cidated. Thus, it is reasonable to think of Poly(I:C) and other forms of
MIA in animals as models of particular neurobehavioral phenotypes
(Fernando & Robbins, 2011) rather than models for speciﬁc diseases.
Furthermore, just as genes do not encode for psychopathologies (Tan
et al., 2008) environmental disturbances (such as prenatal infection)
alone do not lead to mental illness. Rather, they can be seen as events
associated with an enhanced frequency of alterations in brainmorphol-
ogy and function underlying particular behavioral manifestations,
which have been statistically linked to various sets of conditions sum-
marized in the terminology used to denote apparently distinct mental
disorders.
All things considered, the successful application of MIA animal
models in neuropsychiatric research, speciﬁcally in drug discovery,
will depend on the combined evaluation of a gamut of phenotypic pre-
sentations (endophenotypes) from the molecular to the cellular and
systemic (behavioral) levels.
3. The polyinosinic:polycytidylic acid model in comparison
to other experimental paradigms of maternal immune activation
As is the case for every model, eachMIA paradigm possesses speciﬁc
advantages and disadvantages, and the suitability for the speciﬁc re-
search question to be addressed – from basic neuroscience to the devel-
opment of novel drug targets – needs to be evaluated individually.
An important advantage of Poly(I:C)-assisted MIA over live patho-
gens is that Poly(I:C)-induced “sickness-like behavior”, characterized
by a plethora of endocrine, autonomic and behavioral symptoms
induced by proinﬂammatory cytokines following immune activation,
is restricted to a maximum period of 24–48 h (Cunningham et al.,ies in the HPA axis commonly associated with depression-like behavior in offspring after
way, projecting from the VTA to the NAc and the Amyg, related to schizophrenia, have
to compromise the function of the SN and striatum(Deleidi et al., 2010). Striatal dopamine
hotic treatment (Zuckermanet al., 2003). Alterations to proper cortical functioning in adult
ciatedwith schizophrenia, have been identiﬁed in the Poly(I:C)MIA animalmodel (Zhang
0), and serotonin (Winter et al., 2009) are reported in the NAc, Hipp, and PFC and changes
(I:C) MIA. Structural abnormalities are noted in the Hipp, the striatum, the PFC and lateral
ventral tegmental area, NAc: nucleus accumbens, Amyg: amygdala, SN: substantia nigra,
:polycytidylic acid, MIA: maternal immune activation.
Table 2
Summary of studies using the Poly(I:C) maternal immune activation (MIA) models to investigate neurobiological mechanisms related to pharmacotherapy of psychotic disorders.
Disease
modeled
Reference Drug Class of drug Effects investigated Results
Schizophrenia Zuckerman
et al., 2003
Haloperidol,
clozapine
Typical and atypical
antipsychotics
Impaired latent inhibition in adult offspring
prenatally exposed to MIA
Haloperidol and clozapine reduced latent
inhibition deﬁcits in mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Ozawa et al.,
2006
Haloperidol,
clozapine
Typical and atypical
antipsychotics
Impaired cognitive performance Chronic administration of clozapine improved
cognitive performance in mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Meyer et al.,
2010
Clozapine Atypical antipsychotic Impairment in working memory and reduction
in hippocampal neurogenesis
Chronic administration of clozapine reversed
impairments in working memory of mice
exposed to Poly(I:C)-induced MIA, no rescue
of hippocampal neurogenesis
Schizophrenia Piontkewitz
et al., 2009
Clozapine Atypical antipsychotic Structural pathologies including enlarged lateral
ventricles and reduced hippocampal volumes,
as well as behavioral abnormalities relevant to
schizophrenia
Administration of clozapine during
peri-adolescence prevented emergence of
behavioral abnormalities and structural brain
alterations in adulthood in mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Roenker et al.,
2011
Risperidone,
paliperidone
Atypical
antipsychotics
Elevation of basal extracellular glutamate levels
in cortex
Chronic administration of risperidone and
paliperidone normalized levels of extracellular
glutamate in the cortex of mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Piontkewitz
et al., 2011
Risperidone Atypical antipsychotic Structural (enlarged lateral ventricles, reduced
hippocampal volumes) and behavioral
abnormalities relevant to schizophrenia
Peri-adolescent risperidone prevented
behavioral abnormalities and structural brain
alterations in adulthood in mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Piontkewitz
et al., 2012
Risperidone Atypical antipsychotic Impaired neurogenesis, disturbed
micro-vascularization and loss of
parvalbumin-expressing hippocampal
interneurons
Peri-adolescent risperidone prevented most
neuropathological changes in mice exposed to
Poly(I:C)-induced MIA
Schizophrenia Dickerson &
Bilkey, 2013
Clozapine Atypical antipsychotic Disrupted synchronization of hippocampal and
medial prefrontal neural networks
Acute administration of clozapine rescued
impairment in long-range neural synchrony in
adult mice exposed to Poly(I:C)-induced MIA
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ble time course of infection with live pathogens, the relatively short-
lived and deﬁned immune response elicited by Poly(I:C) allows for the
precise timing of the immunogenic impact, hence allowing for speciﬁc
associations of immune activation with deﬁned stages of embryonic
brain development (Theiler, 1972; Rutledge, 1997). Indeed, several
studies using the Poly(I:C) MIA model have signiﬁcantly contributed
to the elucidation of the distinct time periods during prenatal develop-
ment which seem to constitute speciﬁc windows of vulnerability to en-
vironmental insult. Hence, speciﬁc neurobehavioral alterations in
adulthood are associated with the exposure to MIA at particular stages
of fetal development, as elegantly demonstrated in a series of studies
employing Poly(I:C)-assisted MIA (Meyer, Feldon, Schedlowski, & Yee,
2006; Meyer et al., 2006a, 2006b; Meyer et al., 2007). For example,
MIA at gestational day 9 and gestational day 12.5 have resulted in
schizophrenia-like behavior in adult offspring, such as impaired senso-
rimotor gating, decreased prepulse inhibition and increased startle sen-
sitivity (Meyer et al., 2005 #78; Meyer et al., 2006a, 2006b). Poly(I:C)
administration at gestational day 12.5 has additionally been reported
to induce enhanced anxiety-like behavior (Hsiao et al., 2012) and
depression-like behavior in the offspring (Khan et al., 2014). Alterna-
tively, offspring from Poly(I:C) MIA at later gestational time periods,
such as gestational day 16 or gestational day 17, demonstrated in-
creased seizure susceptibility, reduced social index scores, thigmotaxis,
and cognitive impairment (Ozawa et al., 2006; Pineda et al., 2013), phe-
notypes related to epileptic and cognitive disorders.
The critical relevance of the particular gestational stage during which
maternal immune activation is induced may relate to both maternal and
fetal factors. First, the immune response in the maternal system signiﬁ-
cantly varies during the course of pregnancy (Sargent, 1993; Tinsley
et al., 2009; Chatterjee et al., 2011), thus determining the nature and in-
tensity of exposure of the fetus to inﬂammatory mediators. Second, the
vulnerability of the fetal nervous systemmay depend on the actual devel-
opmental period, as indicated by epidemiological evidence reporting an
increased likelihood for offspring brain and behavioral aberrationsspeciﬁcally associated with maternal infection during the late ﬁrst and
early second trimester of pregnancy (Mednick et al., 1988; Brown et al.,
2004; Atladottir et al., 2010). This observation may relate to the fact that
the development of the immune system is only completed during late
gestation and the postnatal period (Holsapple et al., 2003).
Considering the pleiotropic effects of cytokines on aspects of neuro-
nal morphology, function and survival (Hinze-Selch et al., 1998; Potter
et al., 1999; Marx et al., 2001; Gilmore et al., 2005; Deverman &
Patterson, 2009) the neurodevelopmental and neurobehavioral out-
come after MIA may directly relate to the speciﬁc cytokine status of
the fetal brain at a particular point of development (Meyer et al.,
2006a, 2006b; Lajtha, 2008;Meyer et al., 2008b). Differential permeabil-
ity of the placenta, an immunologically highly active organ (Zourbas
et al., 2001; Bowen et al., 2002; Ostojic et al., 2003), during the course
of pregnancy (Dahlgren et al., 2006) has to be considered as an addition-
al variable determining fetal cytokine exposure and related long-term
consequences. However, the speciﬁc mechanisms underlying the pas-
sage of individual cytokines through thematernal–fetal interface at par-
ticular gestational stages remain incompletely understood (Jonakait,
2007; Lim & Kobzik, 2009).
Apart from the possibility to stringently control the timing, gesta-
tional Poly(I:C) administration also allows for rigorous constraints on
the intensity of the immunogenic stimulation and the associatedmater-
nal immune response. Correspondingly, seminal experiments have
demonstrated a deﬁned dose-dependency of adult behavioral impair-
ments resulting from MIA using the Poly(I:C) model (Meyer et al.,
2005; Fortier et al., 2007; Wolff & Bilkey, 2010).
Furthermore, sex-speciﬁc effects of MIA have been noted pertaining
to differential behavioral outcomes inmale and female offspring (Hodyl
et al., 2007; Schwendener et al., 2009; Bitanihirwe et al., 2010;
Chlodzinska et al., 2011; Enayati et al., 2012; Vorhees et al., 2012;
Bronson & Bale, 2014). Dose-dependency, together with the observed
offspring sex-effects of MIAmay present additional variables to be con-
sidered within a complex set of interacting factors deﬁning neurobe-
havioral outcomes after prenatal infection.
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et al., 2008a; Meyer & Feldon, 2010; Brown, 2011; Giovanoli et al.,
2013), MIAmay constitute one speciﬁc environmental insult impinging
on the speciﬁc genetic make-up of an individual and/or serve as “prim-
ing” factor, predisposing an individual – upon confrontation with fur-
ther challenging stimuli (such as additional stress exposure later in
life; Giovanoli et al., 2013) – to the development of mental illness.
Concerning gene × environment interactions as the biological interface
for the long-established “nature versus nurture” etiological principle,
the Poly(I:C) MIA model has contributed to the elucidation of some of
the key players involved in the pathogenesis of schizophrenia (Ozawa
et al., 2006; Dickerson & Bilkey, 2013; Van den Eynde et al., 2013). For
example, following Poly(I:C)-assisted MIA, mice with mutations in the
Disrupted in Schizophrenia 1 gene (DISC1) – originally identiﬁed in a
case of familial human schizophrenia (Chubb et al., 2008; Jaaro-Peled
et al., 2009) – display higher susceptibility to thedevelopment of behav-
ioral features associated with schizophrenia (Lipina et al., 2013). These
data indicate a potential interplay between proinﬂammatory cytokines
such as interleukin-6 (IL-6) resulting fromMIA (Smith et al., 2007) and
DISC1 in the pathogenesis of schizophrenia spectrum disorders (Chubb
et al., 2008). Additionally, speciﬁc epigenetic modiﬁcations at the DISC1
gene locus upon prenatal Poly(I:C) exposure have been reported
(Connor et al., 2012), adding a further level of complexity to the intri-
cate web of pathomechanisms forming the biological underpinnings of
psychiatric disease development. Similarly, an interaction of Poly(I:C)
MIA with mutations in the nuclear receptor related protein 1 (NURR1)
gene, encoding for a transcription factor controlling dopaminergic de-
velopment, has been found to underlie the effects on behavioral and
neuropathological alterations in the adult offspring (Vuillermot et al.,
2012).
Despite its advantages, there are also limitations to the Poly(I:C)-
based MIA animal paradigm. Apart from the “traditional”, general con-
cerns relating to the usage of rodent systems to model complex neuro-
psychiatric disorders, which present with alterations of inherently
“human” behavioral features, there are also experimental speciﬁcs of
Poly(I:C)-assisted MIA that need to be taken into consideration for the
design and interpretation of individual studies. The major drawback of
using immunogenic manipulations based upon Poly(I:C) or LPS, rather
than live pathogens, is the – albeit well-characterized – limited set
of immune responses elicited (Baldwin, 1996; Cunningham et al.,
2007; Chen et al., 2011; Chlodzinska et al., 2011; Paris et al., 2011;
Arrode-Bruses & Bruses, 2012; Connor et al., 2012; Diz-Chaves et al.,
2012; Babri et al., 2013). Comparatively, stimulating the maternal im-
mune system by administration of a real virus (such as inﬂuenza),
leads to a much broader activation of not only the innate, but also the
acquired immune system, thus more closely resembling the situation
following infection during pregnancy in humans (Meyer, 2014a).
4. The polyinosinic:polycytidylic acid
maternal immune activation model in the
investigation of psychopharmacological treatment approaches
Currently available pharmacological treatment options for both psy-
chotic and mood disorders are still insufﬁcient, with a large percentage
of the patient population not satisfactorily responding to the commonly
prescribed drug regimens (Maes et al., 1997; Buckley et al., 2001;
Conley & Kelly, 2001; Kubera et al., 2001; Gaynes, 2009; El-Hage et al.,
2013; Spijker et al., 2013). Even among the designated “responders”,
complete remission rates remain low (Bisgaard et al., 2007; Buckley
et al., 2001; Mouaffak et al., 2006; Schlaepfer et al., 2013) and patient
compliance is compromised by the frequent experience of adverse
side effects associated with psychopharmacotherapy (Blair & Dauner,
1992; Zimbroff et al., 1997; Bilder et al., 2002; Siegel et al., 2002;
Kroeze et al., 2003; Jaaro-Peled et al., 2009; Abbasi et al., 2010). In the
search for novel therapeutic strategies, the Poly(I:C) MIA rodent
model has become very attractive in recent years due to its well-documented validity, thus far assessed mainly in the context of
schizophrenia-like phenotypes in rats and mice (Zuckerman et al.,
2003; Ozawa et al., 2006; Romero et al., 2007; Meyer, Knuesel,
Nyffeler, & Feldon, 2010; Piontkewitz et al., 2012) and recently begin-
ning to be explored in the context of MDD (Khan et al., 2014). Hence,
Poly(I:C)-assisted MIA serves as a naturalistic animal model to further
characterize molecular and structural neuronal alterations resulting
from the treatment with common psychopharmacological medication.
4.1. Polyinosinic:polycytidylic acid-assisted maternal immune
activation for the investigation of established psychopharmacological drugs
Elucidation of the precise neurobiological mechanisms underlying
the effect of established psychopharmacological drugs, which – al-
though already in therapeutic use for decades – remain incompletely
understood, may aid in the identiﬁcation of alternative, potentially
more speciﬁc drug targets and/or strategies to combat undesired side
effects. For example, treatment with the atypical antipsychotic risperi-
done has been found to rescue aberrant hippocampal neurogenesis,
parvalbumin expression and vascularization resulting from gestational
Poly(I:C) administration in rats (Piontkewitz et al., 2012). Interestingly,
sex-speciﬁcities in the effects of long-term clozapine or risperidone
treatment during adolescence and during adulthood have also been re-
ported (Piontkewitz et al., 2012), which additionally suggests Poly(I:C)
MIA as a preclinical model for the investigation of gender-differences in
disease susceptibility and drug response in psychiatric disorders.
Further, acute treatment with clozapine, the ﬁrst atypical antipsy-
chotic drug available, was reported to reverse impaired long-range neu-
ral synchrony between the hippocampus and medial prefrontal cortex
(mPFC), a particular functional deﬁcit observed in the Poly(I:C) MIA
rat model which is associated with the presentation of schizophrenia-
like behavior (Dickerson & Bilkey, 2013). The effect of clozapine on
the reduced coupling between the mPFC and the hippocampus may
contribute to its therapeutic effects in schizophrenia, and the Poly(I:C)
MIAmodel may serve as a tool to investigate themolecular changes un-
derlying the observed functional deﬁcits, potentially leading to the ex-
ploration of novel intervention strategies targeting these molecules
(Dickerson&Bilkey, 2013). Along these lines, NMDAglutamate receptor
hypofunction, which was effectively blocked by low dose treatment
with paliperidone or risperidone, has been proposed as an early devel-
opmental consequence of prenatal Poly(I:C) exposure. Hence, the
Poly(I:C) MIA model may serve as a tool for the identiﬁcation of early
therapeutic interventions directed at the glutamatergic system, which
is known to also be involved in the manifestation of positive and nega-
tive symptoms in patients suffering from schizophrenia (Roenker et al.,
2011). Supporting the role of NMDA receptors in the mechanistic un-
derpinnings of pharmacotherapy, hippocampal slices of offspring from
Poly(I:C) MIA show NMDA/glutamatergic receptor activity speciﬁcally
related to clozapine and not to haloperidol (Wittmann et al., 2005).
In the case of currently used antidepressant drugs, long-term treat-
ment with either the SSRI ﬂuoxetine or the antipsychotic aripiprazole
has been shown to completely reverse amphetamine-induced locomo-
tor activation in offspring after Poly(I:C)-based MIA (Richtand et al.,
2012). Behavioral effects of antidepressants in this model are especially
important considering recently emerging evidence that not only fea-
tures relevant to the symptomatology of schizophrenia, but also
depressive-like behavior is observed in offspring after prenatal immune
activation using either Poly(I:C) (Khan et al., 2014) or LPS (Babri et al.,
2013; Lin & Wang, 2013).
Thus, in addition to the well-established predictive validity of the
Poly(I:C) MIA rodent model for schizophrenia, the power of the para-
digm as a tool for drug validation and discovery in depression research
is only beginning to be explored. In this fashion, alterations of the glyco-
gen synthase kinase-3 β (GSK-3β) signaling pathway, the target of the
classic mood stabilizer lithium that reduces both depression-like and
manic-like behaviors in rodents (see for review Jope, 2011), in the
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ther applicability in the study of the incompletely understoodmolecular
mechanisms underlying the high treatment efﬁcacy of lithium (Conley
& Kelly, 2001; Basselin et al., 2007; Jope, 2011). This approach could po-
tentially lead to the identiﬁcation of reﬁned drug targets within the rel-
evant signaling pathways. A summary of the studies using the Poly(I:C)
MIA rodentmodel in preclinical research to investigatemechanisms un-
derlying the action of currently prescribed pharmacological treatments
can be found in Table 2.
4.2. Polyinosinic:polycytidylic acid-assisted maternal
immune activation in the discovery of novel therapeutic strategies
Lately, the Poly(I:C) MIA model is emerging as an extremely potent
preclinical research tool in the quest for both symptomatic and preven-
tive treatment approaches aiming to ameliorate or restrict behavioral
and neurobiological dysfunctions resulting from gestational infection.
In both cases, the Poly(I:C) MIAmodel is ideally suited for the develop-
ment, characterization and screening of novel compounds. Symptomat-
ic therapies can be evaluated in the adult offspring without any regard
to possible drug interactions or to the effects of other acute manipula-
tions, which may be potentially confounding in other animal models.
Here, the experimental induction of the phenotype is carried out in-
utero, long before the manifestation and examination of the phenotype
to be studied. Accordingly, the concept of a prenatal manipulation that
gives rise to the manifestation of psychiatric symptoms in adulthood
also represents an advantageous approach by which factors contribut-
ing to the progression of the disease, as well as therapeutic strategies
aiming at preventing the onset of the disease later in life, can be identi-
ﬁed during the individual's adolescent period.
This aspect is particularly relevant in the case of schizophrenia,
where it is known that the entire range of behavioral and associated
neurobiological alterations marking the full-blown disorder usually
emerge during early adulthood, with the adolescent period constituting
a “window of vulnerability” determining onset, course and severity of
the disease (Meyer et al., 2007; Patterson, 2007; Li et al., 2009; Meyer
& Feldon, 2012; Michel et al., 2012; Schimmelmann et al., 2013;
Meyer, 2014b). Here, ground-breaking work has been carried out
using the Poly(I:C) MIA model investigating both the factors con-
tributing to disease manifestation in adulthood (Meyer et al., 2008a;
Vuillermot et al., 2010; Giovanoli et al., 2013), as well as the beneﬁcial
effects of early preventive pharmacological interventions (Piontkewitz
et al., 2009; Meyer, Spoerri, Yee, Schwarz, & Feldon, 2010; Piontkewitz
et al., 2012).
Most of these studies focus on schizophrenia, which is commonly
classiﬁed as a “neurodevelopmental disorder” (Piontkewitz et al.,
2012; Zhang et al., 2012), and in which a clinically latent period during
childhood (pediatric schizophrenia is very rare; Brent et al., 2013) is
followed by a clinically validated prodromal stage duringwhichpatients
present with vague and unspeciﬁc symptoms (Brent et al., 2013). Ac-
cordingly, early therapeutic interventions during the peri-adolescent
periodmay exploit awindowof opportunity for preventing disease pro-
gression and consequently associated negative impacts on patients' per-
sonal, social and professional lives, as well as augmented risks for the
development of additional psychiatric diseases. Interestingly, chronic
treatment during peri-adolescence with not only antipsychotic, but
also antidepressantmedication has been reported to effectively prevent
schizophrenia-like behavior after prenatal exposure to Poly(I:C) (Meyer
et al., 2010), paralleling results of a human study (Cornblatt et al., 2007).
However, although sub-threshold symptoms during adolescence are
similarly known to confer heightened risks of later depression and sui-
cidal behaviors (Fergusson et al., 2005), the potential effects of preven-
tive treatment on the depression-like phenotype in adulthood observed
after Poly(I:C) MIA (Khan et al., 2014) have not yet been investigated.
In the light of evidence indicating that the duration of untreated
psychiatric manifestations is not only associated to the extent ofpsychosocial damage suffered (Ho et al., 2000), but also correlates to
the subsequent responsiveness to pharmacological treatment (Ho
et al., 2003; Marshall et al., 2005; Perkins et al., 2005; Melle et al.,
2008; Farooq et al., 2009), the possibility to prevent disease outbreak
by early pharmacological intervention seems very appealing. However,
there are important limitations and concerns related to early preventive
drug treatment (see for review Francey et al., 2010). Importantly, the
ability to properly anticipate– at early stagesof (disease) development–
individuals who are at high risk for the development of psychiatric dis-
orders entirely depends on the validity and the predictive power of the
criteria applied (Francey et al., 2010). With a current transition rate of
less than 20% for psychotic disorders (Yung et al., 2008; Ruhrmann
et al., 2010), the number of subjects who would be receiving unneeded
psychopharmacological treatment (“false-positives”) is high and raises
important ethical concerns (Block, 2006), especially considering that
the corresponding experimental research is still in its infancy. Here
the Poly(I:C)-assisted MIA in rodents constitutes a highly relevant tool
for the budding exploration, in a preclinical research setting, of both
beneﬁcial as well as adverse effects associated with early preventive
drug treatment. Indeed, using the Poly(I:C) MIA mouse model it was
found that chronic psychopharmacotherapy during the peri-
adolescent period in “healthy” control animals (corresponding to
false-positive subjects in the human population) resulted in an en-
hanced risk for behavioral alterations later in life (Meyer et al., 2010).
These data highlight the necessity for further characterization at the
molecular, cellular and behavioral levels of the full spectrum of – so far
incompletely understood – intermediate and long-term consequences
resulting from early preventive drug treatment regimes. The Poly(I:C)
MIA model is proposed as an ideal tool for addressing these questions
as differential effects of pharmacotherapy can be evaluated in “true”
high-risk (i.e. offspring having undergone prenatal Poly(I:C) exposure)
and “false-positive” (i.e. offspring having undergone vehicle control ex-
posure) individuals in parallel. Moreover, Poly(I:C)-assisted MIA is a
highly suitable paradigm in the search for novel preventive therapeutic
strategies as it recapitulates the neurodevelopment aspect related to the
etiology of psychiatric conditions, including psychotic and mood disor-
ders (Meyer et al., 2005; Meyer et al., 2010). Indeed, several studies
taking advantage of the Poly(I:C) MIA model to identify additional pre-
ventive pharmacological approaches have recently emerged. One
example is the use of antibiotic therapies in order to attenuate the pro-
gression of behavioral as well as cellular and molecular deﬁcits related
to neuropsychiatric disease development (Mattei et al., 2014; Zhu
et al., 2014).
Similarly, the successful application of the Poly(I:C)MIA paradigm in
the quest to identify new symptomatic treatment options for neuropsy-
chiatric conditionswill require the integration of the effects of candidate
molecules on Poly(I:C) MIA-induced alterations— from the single mol-
ecule via the neural circuitry to the behavioral level (see Fig. 3). Exam-
ples for such approaches include a recent rat μPET study which in a
longitudinal assessment of dynamic protein expression changes, report-
ed age- and region-speciﬁc impairment of the endocannabinoid system
in Poly(I:C) offspring (Verdurand et al., 2014). This study supports the
use of Poly(I:C) MIA in the targeted and detailed analysis of the patho-
genic and therapeutic relevance of molecules associated with the
endocannabinoid signaling pathway, which has been previously related
to several neuropsychiatric conditions, including schizophrenia and de-
pression (see for reviewMarco et al., 2011). In the case of ASD, forwhich
the Poly(I:C) MIA rodent model has been also repeatedly validated
(Schwartzer et al., 2013; Missault et al., 2014), recent results using
this model suggest hyperpurinergia to be fundamental to the observed
deﬁciencies, as well as being highly treatable — thereby potentially re-
ﬁning therapeutic strategies for ASD (Naviaux et al., 2014; Naviaux
et al., 2013). Intriguingly, the purinergic signaling system is also impli-
cated in the pathogenesis of both MDD (Cao et al., 2013) and schizo-
phrenia (Burnstock et al., 2011; Wonodi et al., 2011), highlighting the
Poly(I:C) MIA model as a valuable model system for the investigation
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between these three intricate neuropsychiatric disorder complexes.
Hence, these diseasesmay not only presentwith overlapping clinical
and therapeutic features, butmay also share some of the underlying eti-
ological bases. In this vein, accumulating evidence suggests a vital role of
epigenetic modiﬁcations, including dynamic posttranslational modiﬁ-
cations to histones, in the pathophysiology of these mental illnesses
(Darnaudéry & Maccari, 2008; Mueller & Bale, 2008; Brown, 2011;
Uchida et al., 2011; Connor et al., 2012; Tang et al., 2013) and therapeu-
tic concepts based upon these observations are under development
(Feder et al., 2009; Masi & Brovedani, 2011; Anderson et al., 2013).
Indeed, global changes of histone acetylation and methylation statuses
as well as promoter-speciﬁc alterations have been identiﬁed in the
brains of offspring after prenatal exposure to Poly(I:C) (Tang et al.,
2013). In contrast, another recent report concludes that maternal im-
mune stimulation by Poly(I:C) may not signiﬁcantly alter epigenetic
regulation of gene expression in the cerebral cortex of adult offspring
(Connor et al., 2012).
These conﬂicting data highlight the relevance of future research in
order to clarify the contribution of epigenetic mechanisms to the ob-
served behavioral and molecular alterations associated with neuropsy-
chiatric disorders.
5. Conclusions and future perspectives
The currently most widely accepted concept – supported by evi-
dence from epidemiological, clinical as well as basic neuropsychiatric
research – proposes a convoluted web of multiple interacting factors
to constitute the biological underpinnings of complex neuropsychiatric
disorders. Here, the ancient perception of “nature versus nurture” is
reﬂected in gene× environment interactionswith various different envi-
ronmental factors additionally interacting with each other. One envi-
ronmental factor repeatedly emerging as critical for the etiology of
several major mental disorders, including schizophrenia, autism and
depression, is gestational infection. Increasing the understanding – at
the molecular, cellular and systemic levels – of the pathomechanisms
involved in these burdensome diseases is a prerequisite for improving
the still unsatisfactory pharmacotherapeutic options available today.
Within this framework, we propose the rodent model of maternal im-
mune activation, based upon the stimulation of the pregnant dam
with Poly(I:C), as a relevant and suitable tool for preclinical drug re-
search, as summarized in the following points previously outlined in
this review:
1) Feasibility and reproducibility of the experimental handling
2) Control over speciﬁc stimulation intensity and precise timing
3) Sensitivity to treatment with available psychopharmacological
agents
4) Exemplarily demonstrated interaction with determined genetic
factors
5) Evidence for interaction with distinct environmental impacts
6) Modeling of disease progression as opposed to single-point acute
manipulation(s)
7) Development and testing of novel preventive and symptomatic ther-
apeutic strategies.
Nevertheless, regarding the conceptual comprehension of the etiol-
ogy of themental illnesses outlined above, and inherent to theuse of an-
imalmodels in neuropsychiatric research, several important constraints
need to be taken into account:
1) Some symptoms of human (psychiatric) disorders currently are –
and will most likely remain – impossible to model in experimental
animals.
2) No single animalmodel can reproduce the entire spectrumof behav-
ioral and neuropathological features characteristic of a psychiatric
entity in the human population.3) Current criteria deﬁning the validity of animal models will need to
be reﬁned as our understanding of the neurobiological bases under-
lying the particular diseases increases, possibly leading to retrospec-
tive re-evaluation of existing paradigms.
4) Maternal immune activation, based upon Poly(I:C), or any other ges-
tational infection/immune challenge procedure, has to be consid-
ered as a model for one, developmentally-based, environmental
challenge condition, rather than as a complete recapitulation of an
entire neuropsychiatric phenotype.
5) Maternal immune activation most likely constitutes a shared patho-
genic feature involved in the etiology of several severe mental ill-
nesses, rather than a model for an individual disease.
6) The complex web of vulnerability factors interacting at the genetic,
epigenetic and environmental levels contributing to the pathogene-
sis of mental illness, remains incompletely understood to date.
7) Our understanding of the longitudinal aspect of disease progression
of psychiatric disorders with a proposed background of neuro-
developmental disturbances, as well as relevance and consequences
of early preventive interventions, is currently still limited.
Taken together, the rodent Poly(I:C) maternal immune activation
protocol is suggested as a valuable experimental approach on the path
to the development of new therapeutic strategies aiming at combating
highly complex and debilitating humanpsychiatric diseases. The fruitful
application of this model in neuropsychiatric drug discovery, however,
will critically depend on the implementation of an analytical strategy
which combines behavioral assessments with the evaluation of various
endophenotypes in order to improve the chances for successful transla-
tion of newly discovered treatment approaches to clinical applications.
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